



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

AUGUST 9, 2024

PTAS

MS. MEGUMI TADENUMA
CRINETICS PHARMACEUTICALS, INC.
6055 LUSK BLVD
SAN DIEGO, CA 92121

508696503

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 08/08/2024

REEL/FRAME: 068229/0843
NUMBER OF PAGES: 9

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: P00032-WO

ASSIGNOR:
KIM, SUN HEE

DOC DATE: 07/29/2024

ASSIGNOR:
ZHAO, JIAN

DOC DATE: 08/05/2024

ASSIGNOR:
ZHU, YUNFEI

DOC DATE: 07/29/2024

ASSIGNEE:
CRINETICS PHARMACEUTICALS, INC.
6055 LUSK BLVD.
SAN DIEGO, CALIFORNIA 92121

APPLICATION NUMBER:
PATENT NUMBER:
PCT NUMBER: US2437537

FILING DATE: 07/11/2024
ISSUE DATE:

TITLE: SOMATOSTATIN SUBTYPE RECEPTOR 3 (SSTR3) AGONISTS AND USES
THEREOF

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

PATENT ASSIGNMENT

WSGR Docket Nos. 48369-758.601
P00032-WO

The undersigned:

1. Sun Hee KIM
San Diego, CA (US)
2. Jian ZHAO
San Diego, CA (US)
3. Yunfei ZHU
San Diego, CA (US)

(the “Inventor(s)”), desire to assign the entire right, title and interest in and to the Inventions and Assigned Patents (each, as defined below) to Crinetics Pharmaceuticals, Inc., a corporation incorporated under the laws of the State of Delaware, having a place of business at 6055 Lusk Blvd., San Diego, CA 92121, (the “Assignee”), and Assignee desires to acquire such right, title and interest, all on the terms and conditions set forth in this Patent Assignment.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) have invented certain new and useful inventions and improvements disclosed in the following patent(s) and patent application(s):

SOMATOSTATIN SUBTYPE RECEPTOR 3 (SSTR3) AGONISTS AND USES THEREOF

for which International Application number PCT/US2024/037537 filed on July 11, 2024 in the receiving office of the United States Patent and Trademark Office,

(the “Listed Patent(s)”). As used herein: “Assigned Patents” means (a) the Listed Patent(s), (b) all Patents that share priority with or claim priority to or from the Listed Patent(s), including each and every Patent that is a divisional, substitution, continuation, continuation-in-part, non-provisional, or national phase application of any of the Listed Patent(s), (c) all Patents applied for on an invention disclosed within the Patents included in foregoing subclauses (a)-(b), (d) each and every Patent granting, issuing or reissuing from any of the foregoing under subclauses (a)-(c), (e) each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing under subclauses (a)-(d), and (f) each and every Patent filed outside the United States and corresponding to any of the foregoing under subclauses (a)-(e). “Patents” means (i) patents, certifications of inventions, inventor’s certificates and other forms of protection granted on any invention in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise, and (ii) applications therefor (whether provisional, converted provisional, utility, design, plant, utility model, non-provisional or otherwise).

2. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to the Assigned Patents, including the right to claim priority to and from said Assigned Patents; (b) in and to the inventions disclosed in the Assigned Patents, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (the “Inventions”) and (c) in and to all claims for past, present and future infringement of the Assigned Patents, including all rights to sue for and to receive and recover for Assignee’s own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Assigned Patents.


3. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for filing, prosecuting or maintaining any of the Assigned Patents; (c) for filing, prosecuting or maintaining applications for reissuance of any said Assigned Patents; (d) for interference or other priority proceedings involving said Assigned Patents or Inventions; and (e) for legal proceedings involving said Inventions or Assigned Patents, including without limitation reissues and reexaminations, IPRs, opposition and other post-grant proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

4. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

5. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

6. Said Inventor(s) hereby request that any Assigned Patents issuing or granting in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued or granted in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

7. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

PATENT ASSIGNMENT		WSGR Docket Nos. 48369-758.601 P00032-WO
IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:		
Date: <u>07/29/2024</u>	<u></u>	
	Sun Hee KIM	
Date: _____	_____	
	Jian ZHAO	
Date: _____	_____	
	Yunfei ZHU	
RECEIVED AND AGREED TO BY ASSIGNEE: Crinetics Pharmaceuticals, Inc.		
Date: <u>August 8, 2024</u>	<u></u>	
	Name: Garlan Adams	
	Title: General Counsel	


PATENT ASSIGNMENT	WSGR Docket Nos. 48369-758.601 P00032-WO
IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:	
Date: _____ Sun Hee KIM	
Date: <u>02/05/2024</u> _____ Jian ZHAO	
Date: _____ Yunfei ZHU	
RECEIVED AND AGREED TO BY ASSIGNEE: Crinetics Pharmaceuticals, Inc. Date: <u>Aug 18, 2024</u> Signature: _____ Name: Garlan Adams Title: General Counsel	

PATENT ASSIGNMENT	WSGR Docket Nos. 48369-758.601 P00032-WO
IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:	
Date: _____ Sun Hee KIM	
Date: _____ Jian ZHAO	
Date: 07/29/24 _____ Yunfei ZHU	
RECEIVED AND AGREED TO BY ASSIGNEE: Crinetics Pharmaceuticals, Inc. Date: _____ Signature: _____ Name: Garlan Adams Title: General Counsel	

PATENT ASSIGNMENT

WSGR Docket Nos. 48369-758.601
P00032-WO

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: _____
Sun Hee KIMDate: _____
Jian ZHAODate: _____
Yunfei ZHURECEIVED AND AGREED TO BY ASSIGNEE: **Crinetics Pharmaceuticals, Inc.**Date: August 8, 2024 Signature: 
Name: Garlan Adams
Title: General Counsel



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

JULY 26, 2023

PTAS

FINNEGAN
901 NEW YORK AVENUE, N.W.
WASHINGTON, DC 20001

508028392

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 07/25/2023

REEL/FRAME: 064371/0312
NUMBER OF PAGES: 8

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: 16187.6000-00000

ASSIGNOR:
KIM, SUN HEE

DOC DATE: 07/19/2023

ASSIGNOR:
ZHAO, JIAN

DOC DATE: 07/21/2023

ASSIGNOR:
ZHU, YUNFEI

DOC DATE: 07/19/2023

ASSIGNEE:
CRINETICS PHARMACEUTICALS, INC.
10222 BARNES CANYON ROAD, BUILDING
#2
SAN DIEGO, CALIFORNIA 92121

APPLICATION NUMBER: 63513599

FILING DATE: 07/14/2023

PATENT NUMBER:

ISSUE DATE:

TITLE: SOMATOSTATIN SUBTYPE RECEPTOR 3 (SSTR3) AGONISTS AND USES
THEREOF

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

ASSIGNMENT

WHEREAS WE are the below-named inventor(s) (hereinafter referred to as Assignor(s)) of an invention entitled:

SOMATOSTATIN SUBTYPE RECEPTOR 3 (SSTR3) AGONISTS AND USES THEREOF

as disclosed and claimed in the application identified below this paragraph:

Application Number	Country of Filing	Filing Date
63/513,599	US	July 14, 2023

WHEREAS, Crinetics Pharmaceuticals, Inc., a corporation incorporated under the laws of the State of Delaware, having a place of business at 10222 Barnes Canyon Road, Building #2, San Diego, CA 92121 (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to all applications for patents on this invention in all countries throughout the world, including any PCT International Application and all national stage applications based thereon that may be filed, and all patents issued upon such applications in all countries throughout the world;

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, WE, as Assignor(s), have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, our entire right, title, and interest in and to this invention, the above-referenced applications that disclose and claim this invention, any PCT International Application and all national stage applications based thereon that may be filed, any other applications for patents filed anywhere in the world that claim this invention, and all divisions, and continuations of any such application, and all patents which may be granted thereon, and all reissues thereof, and all rights to claim priority in any country on the basis of any such applications, and all extensions, renewals, and reissues thereof; and WE hereby authorize and request that any official of any country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, WE covenant that WE have the full right to convey the interest assigned by this Assignment, and WE have not executed and will not execute any agreement in conflict with this Assignment;

AND, WE further covenant and agree that WE will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me/us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

IN TESTIMONY WHEREOF, WE have hereunto set our hands.

ASSIGNOR (Inventor) 1

Sun Hee Kim

Signature

Sun Hee Kim

Print Name

07/19/2023

Execution Date

ASSIGNOR (Inventor) 2

Signature

Jian Zhao

Print Name

Execution Date

ASSIGNOR (Inventor) 3

Signature

Yunfei Zhu

Print Name

Execution Date

Assignee Name: Grinetics Pharmaceuticals, Inc.

Signature:

Printed Name:

Garlan Adams

Corporate Title:

General Counsel

Date:

July 21, 2023

ASSIGNMENT

WHEREAS WE are the below-named inventor(s) (hereinafter referred to as Assignor(s)) of an invention entitled:

SOMATOSTATIN SUBTYPE RECEPTOR 3 (SSTR3) AGONISTS AND USES THEREOF

as disclosed and claimed in the application identified below this paragraph:

Application Number	Country of Filing	Filing Date
63/513,599	US	July 14, 2023

WHEREAS, Crinetics Pharmaceuticals, Inc., a corporation incorporated under the laws of the State of Delaware, having a place of business at 10222 Barnes Canyon Road, Building #2, San Diego, CA 92121 (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to all applications for patents on this invention in all countries throughout the world, including any PCT International Application and all national stage applications based thereon that may be filed, and all patents issued upon such applications in all countries throughout the world;

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, WE, as Assignor(s), have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, our entire right, title, and interest in and to this invention, the above-referenced applications that disclose and claim this invention, any PCT International Application and all national stage applications based thereon that may be filed, any other applications for patents filed anywhere in the world that claim this invention, and all divisions, and continuations of any such application, and all patents which may be granted thereon, and all reissues thereof, and all rights to claim priority in any country on the basis of any such applications, and all extensions, renewals, and reissues thereof; and WE hereby authorize and request that any official of any country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, WE covenant that WE have the full right to convey the interest assigned by this Assignment, and WE have not executed and will not execute any agreement in conflict with this Assignment;

AND, WE further covenant and agree that WE will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me/us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

IN TESTIMONY WHEREOF, WE have hereunto set our hands.


ASSIGNOR (Inventor) 1

Signature

Sun Hee Kim
Print Name

Execution Date

ASSIGNOR (Inventor) 2


Signature

Jian Zhao
Print Name

Execution Date

07/21/2023
Execution Date

ASSIGNOR (Inventor) 3


Signature

Yunfei Zhu
Print Name

Execution Date

Execution Date

Assignee Name: Grinetics Pharmaceuticals, Inc.

Signature: 

Printed Name:

Garann Adams

Corporate Title:

General Counsel

Date:

July 21, 2023

ASSIGNMENT

WHEREAS WE are the below-named inventor(s) (hereinafter referred to as Assignor(s)) of an invention entitled:

SOMATOSTATIN SUBTYPE RECEPTOR 3 (SSTR3) AGONISTS AND USES THEREOF

as disclosed and claimed in the application identified below this paragraph:

Application Number	Country of Filing	Filing Date
63/513,599	US	July 14, 2023

WHEREAS, Crinetics Pharmaceuticals, Inc., a corporation incorporated under the laws of the State of Delaware, having a place of business at 10222 Barnes Canyon Road, Building #2, San Diego, CA 92121 (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to all applications for patents on this invention in all countries throughout the world, including any PCT International Application and all national stage applications based thereon that may be filed, and all patents issued upon such applications in all countries throughout the world;

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, WE, as Assignor(s), have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, our entire right, title, and interest in and to this invention, the above-referenced applications that disclose and claim this invention, any PCT International Application and all national stage applications based thereon that may be filed, any other applications for patents filed anywhere in the world that claim this invention, and all divisions, and continuations of any such application, and all patents which may be granted thereon, and all reissues thereof, and all rights to claim priority in any country on the basis of any such applications, and all extensions, renewals, and reissues thereof; and WE hereby authorize and request that any official of any country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, WE covenant that WE have the full right to convey the interest assigned by this Assignment, and WE have not executed and will not execute any agreement in conflict with this Assignment;

AND, WE further covenant and agree that WE will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me/us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

IN TESTIMONY WHEREOF, WE have hereunto set our hands.

ASSIGNOR (Inventor) 1

Signature

Sun Hee Kim

Print Name

Execution Date

ASSIGNOR (Inventor) 2

Signature

Jian Zhao

Print Name

Execution Date

ASSIGNOR (Inventor) 3

[Signature]

Signature

Yunfei Zhu

Print Name

07-19-2023

Execution Date

Assignee Name: Crinetics Pharmaceuticals, Inc.

Signature: [Signature]

Printed Name: Garlan Adams

Corporate Title: General Counsel

Date: July 24, 2023